CRISPR Therapeutics Announces European Patent for CRISPR/Cas Gene Editing
CRISPR Therapeutics reports that the European Patent Office (EPO) has announced its intention to grant a patent broadly covering CRISPR’s in-licensed gene editing technology.
The European patent application received many third-party observations filed by the Broad Institute and others attempting to prevent or delay this grant. After reviewing these submissions, the EPO determined that the evidence and legal arguments didn’t affect the patentability of the inventions by the applicants, and announced its intention to advance the case to grant in Europe.
